AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00548743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: usual care for identification and management of postpartum depression
Study NCT04623762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: yoga application
Study NCT01537692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA Nasal Aerosol
Description: BDP HFA Nasal 80mcg
Study NCT01537692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA Nasal Aerosol
Description: BDP HFA Nasal 320mcg
Study NCT01537692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP HFA Inhalation Aerosol (QVAR)
Description: BDP HFA Oral 320mcg
Study NCT02036138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy
Study NCT02036138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Study NCT02036138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Medical Therapy
Study NCT02723227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
Study NCT02723227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Social Services
Study NCT02723227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Social Services
Study NCT02565524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetic and phenotypic profile
Description: Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
Study NCT04089397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
Study NCT03837951 — intervention group
Intervention type: OTHER
Intervention: Figure-of-eight tape measure measurements on both hands
Description: Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.
Study NCT03837951 — intervention group
Intervention type: OTHER
Intervention: Volumeter measurements
Description: Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
Study NCT00566540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
Study NCT00566540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
Study NCT00566540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
Description: Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
Study NCT00566540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple endoscopy and biopsy
Description: Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
Study NCT00512486 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-563
Description: BIW-8405/MEDI-563 administered at one of five dose levels:~* 0.03 mg/kg intravenous injection~* 0.1 mg/kg intravenous injection~* 0.3 mg/kg intravenous injection~* 1.0 mg/kg intravenous injection~* 3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection
Study NCT00648999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
Study NCT03882151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: electrical source imaging
Description: automated analysis of surface EEG with electrocal source imaging
Study NCT03833791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education and modifying diet
Description: The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
Study NCT03833791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education, modifying diet and physical activity prescription
Description: One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity.
Study NCT03488680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Behavior change communication about optimal complementary feeding
Study NCT01441219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon 2
Description: Ingest one colon 2 capsule
Study NCT01267773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Study NCT01267773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Treatment
Study NCT03204162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Coaching
Description: Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
Study NCT00872053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes.
Study NCT00872053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
Study NCT00224744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultracision
Description: Surgery by Ultracision
Study NCT00224744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classical lymphadenectomy
Description: classical lymphadenectomy
Study NCT00148668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
Study NCT00148668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: Weekly injections given starting week 3 and ending week 14
Study NCT00148668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Given every three weeks starting week 3 and ending on week 14
Study NCT00148668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given every three weeks starting week 3 and ending on week 14
Study NCT03214770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
Study NCT03214770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: light-cured calcium hydroxide
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
Study NCT03853551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
Study NCT01249846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioChip ®
Study NCT01249846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PerioChip ®
Study NCT03120429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fish group
Description: Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
Study NCT03120429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will have hypo-energetic diet in which subjects have no seafood.
Study NCT04727138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546 Powder for Oral Suspension
Description: EXS21546 Powder for Oral Suspension
Study NCT04727138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546 Granule in Capsule
Description: EXS21546 Granule in Capsule
Study NCT04727138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Interaction
Study NCT04727138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Interaction
Study NCT04727138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Effect
Description: Fed/Fasted
Study NCT04727138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food Effect
Description: Fed/Fasted
Study NCT04727138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Suspension
Description: Placebo Powder for Oral Suspension
Study NCT01653600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S.M.A.R.T CONTROL Stent
Description: Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
Study NCT01653600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent
Description: same to SMART STENT
Study NCT03529708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D CRT plus SBRT boost
Description: Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
Study NCT02028780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to dose
Description: placebo
Study NCT02028780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: short infusion
Study NCT02028780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Idarucizumab
Description: Placebo to Idarucizumab
Study NCT02028780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: 2 capsules dabigatran
Study NCT01510964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prompt-sheet
Description: Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology.
Study NCT01510964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group
Description: Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist
Study NCT02855710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rhythm workers training Perceptive timing
Description: Perceptive timing training
Study NCT02855710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rhythm workers training sensorimotor timing
Description: Sensorimotor timing training
Study NCT02855710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Rhythm workers training
Description: No training
Study NCT02484768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: Intravenous treatment
Study NCT02484768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Intravenous treatment
Study NCT01168609 — intervention group
Intervention type: PROCEDURE
Intervention: Primary percutaneous coronary intervention
Description: Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
Study NCT03457324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCM-16021
Description: This prescription with seven ingredients.
Study NCT03457324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04446429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: 200 mg q.d.
Study NCT04446429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as determined by the PI
Study NCT03005639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib and Cobimetinib
Description: All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
Study NCT00179764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immunoablative Hematopoietic PBSC Transplant
Description: Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
Study NCT03845270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab + docetaxel
Description: Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
Study NCT01088542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communities That Care
Description: The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
Study NCT00179764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Busulfan pharmacokinetics
Description: Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
Study NCT00179764 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Central Nervous System (CNS) prophylaxis radiation
Description: * Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant.
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-related affective problems analysis
Description: Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
Study NCT03846544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitoropin alfa (CFA)-double pick up
Description: In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
Study NCT03839615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regenerations
Description: intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study NCT03839615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided bone regenerations
Description: intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study NCT01247675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon hGH)
Description: s.c., weekly injection
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control toothpaste containing no anti-cavity ingredients
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste containing no anti-cavity ingredients
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control toothpaste containing no anti-cavity ingredients
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental toothpaste containing fluoride and amino acid (arginine)
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental toothpaste containing fluoride and amino acid (arginine)
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.